{"id":"NCT00781274","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","officialTitle":"A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2008-10-28","resultsPosted":"2012-08-20","lastUpdate":"2014-05-02"},"enrollment":32,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"MP-424","otherNames":["Telaprevir"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]},{"type":"DRUG","name":"Peginterferon Alfa-2b","otherNames":[]}],"arms":[{"label":"MP-424","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.","primaryOutcome":{"measure":"The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","timeFrame":"After 24 weeks of follow-up","effectByArm":[{"arm":"MP-424","deltaMin":34.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["22239511"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":32},"commonTop":["Anaemia","Pyrexia","Blood uric acid increased","Malaise","White blood cell count decreased"]}}